Complement C3-Targeted Therapy: Replacing Long-Held Assertions with Evidence-Based Discovery
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Complement dysregulation underlies several inflammatory disorders, and terminal complement inhibition has thus far afforded significant clinical gains. Nonetheless, emerging pathologies, fueled by complement imbalance and therapy-skewing genetic variance, underscore the need for more comprehensive, disease-tailored interventions. Modulation at the level of C3, a multifaceted orchestrator of the complement cascade, opens up prospects for broader therapeutic efficacy by targeting multiple pathogenic pathways modulated by C3-triggered proinflammatory crosstalk. Notably, C3 intervention is emerging as a viable therapeutic strategy for renal disorders with predominantly complement-driven etiology, such as C3 glomerulopathy (C3G). Using C3G as a paradigm, we argue that concerns about the feasibility of long-term C3 intervention need to be placed into perspective and weighed against actual therapeutic outcomes in prospective clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rother, R. P., Rollins, S. A., Mojcik, C. F., Brodsky, R. A., & Bell, L. (2007) · Nature Biotechnology · doi:10.1038/nbt1344 · Cited by 778 · cited 9×
“From a different standpoint, therapeutic targeting of the terminal pathway, either by C5 blockade or inhibition of C5a-triggered activation of effector responses, represents a viable approach for containing clinical manifestations that are largely driven by terminal pathway effectors (such as C5a and the MAC).”
BackgroundInfluential
Cited by
Complement in cancer: untangling an intricate relationship
Reis, E. S., Mastellos, D. C., Ricklin, D., Mantovani, A., & Lambris, J. D. (2018) · Nature Reviews Immunology · doi:10.1038/nri.2017.97 · Cited by 425
Self-citationThe renaissance of complement therapeutics
Ricklin, D., Mastellos, D. C., Reis, E. S., & Lambris, J. D. (2018) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.156 · Cited by 379
Self-citationClinical promise of next-generation complement therapeutics
Mastellos, D. C., Ricklin, D., & Lambris, J. D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0031-6 · Cited by 343
Self-citationA guide to complement biology, pathology and therapeutic opportunity
Mastellos, D. C., Hajishengallis, G., & Lambris, J. D. (2024) · Nature Reviews Immunology · doi:10.1038/s41577-023-00926-1 · Cited by 320
Self-citationThe challenges and promise of complement therapeutics for ocular diseases
Park, D. H., Connor, K. M., & Lambris, J. D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01007 · Cited by 108
Self-citation
Metadata
- Authors
- Mastellos, D. C., Reis, E. S., Ricklin, D., Smith, R. J., & Lambris, J. D.
- Venue
- Trends in Immunology
- Publisher
- Elsevier BV
- Published
- 2017-06
- Volume
- 38
- Issue
- 6
- Pages
- 383-394
- ISSN
- 1471-4906 (ISSN-L)
- OpenAlex
- W2606241786
- Cited by
- 42
- References
- 1
- FWCI
- 0.32
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.